NuVasive (NUVA) Tops Q4 EPS by 4c, Revenues Miss

NuVasive (NASDAQ: NUVA) reported Q4 EPS of $0.59, $0.04 better than the analyst estimate of $0.55. Revenue for the quarter came in at $291.8 million versus the consensus estimate of $298.36 million.

Fourth Quarter 2020

• Net sales decreased 6.0% to $291.8 million, or 6.7% on a constant currency basis;
• GAAP operating margin of 6.9%; Non-GAAP operating margin of 15.8%; and
• GAAP diluted earnings per share of $0.03; Non-GAAP diluted earnings per share of $0.59.

"NuVasive continues to see significant impact from COVID-19 on elective surgical procedures and patient sentiment, particularly within the U.S. market, which increased late in the fourth quarter," said J. Christopher Barry, chief executive officer of NuVasive. "Against a challenging 2020, we made key investments in infrastructure, talent, and innovation to unlock our ability to fulfill our long-term strategy. We are excited about the acquisition of Simplify Medical to advance our C360 portfolio and the 510(k) submission for the Pulse platform. We remain committed to delivering enhanced value to shareholders, surgeons, and employees, while helping change the lives of patients around the globe."

For earnings history and earnings-related data on NuVasive (NUVA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c